TY - JOUR
T1 - Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis
T2 - a multi-national multi-database case-control study
AU - Newby, Danielle
AU - Prieto-Alhambra, Daniel
AU - Duarte-Salles, Talita
AU - Ansell, David
AU - Pedersen, Lars
AU - Van Der Lei, Johan
AU - Mosseveld, Mees
AU - Rijnbeek, Peter
AU - James, Glen
AU - Alexander, Myriam
AU - Egger, Peter
AU - Podhorna, Jana
AU - Stewart, Robert
AU - Perera, Gayan
AU - Avillach, Paul
AU - Grosdidier, Solène
AU - Lovestone, Simon
AU - Nevado-Holgado, Alejo J.
PY - 2020/4/6
Y1 - 2020/4/6
N2 - Background: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk. Methods: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia. Results: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57-1.37). Conclusions: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.
AB - Background: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk. Methods: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia. Results: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57-1.37). Conclusions: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.
KW - Anti-inflammatory drugs
KW - Case-control study
KW - Dementia
KW - DMARDs
KW - EMIF
KW - European Medical Information Framework
KW - Inflammation
KW - Methotrexate
KW - Rheumatoid arthritis
KW - Sulfasalazine
UR - http://www.scopus.com/inward/record.url?scp=85083071675&partnerID=8YFLogxK
U2 - 10.1186/s13195-020-00606-5
DO - 10.1186/s13195-020-00606-5
M3 - Article
C2 - 32252806
AN - SCOPUS:85083071675
SN - 1758-9193
VL - 12
SP - 38
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
M1 - 38
ER -